JP3278273B2
(ja)
*
|
1993-12-17 |
2002-04-30 |
キヤノン株式会社 |
薬剤徐放性カプセル
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
WO1998025963A1
(en)
|
1996-12-13 |
1998-06-18 |
Chiron Corporation |
Analysis and separation of platelet-derived growth factor proteins
|
US5985214A
(en)
|
1997-05-16 |
1999-11-16 |
Aurora Biosciences Corporation |
Systems and methods for rapidly identifying useful chemicals in liquid samples
|
NZ503513A
(en)
|
1997-09-18 |
2004-12-24 |
Skyepharma Inc |
Sustained-release liposomal anesthetic compositions
|
AU9363798A
(en)
|
1997-11-06 |
1999-05-31 |
Chiron S.P.A. |
Neisserial antigens
|
WO1999025319A1
(en)
|
1997-11-14 |
1999-05-27 |
Depotech Corporation |
Production of multivesicular liposomes
|
CA2317815A1
(en)
|
1998-01-14 |
1999-07-22 |
Chiron S.P.A. |
Neisseria meningitidis antigens
|
ES2304065T3
(es)
|
1998-05-01 |
2008-09-01 |
Novartis Vaccines And Diagnostics, Inc. |
Antigenos y composiciones de neisseria meningitidis.
|
AU1316200A
(en)
|
1998-10-15 |
2000-05-01 |
Chiron Corporation |
Metastatic breast and colon cancer regulated genes
|
PT1141331E
(pt)
|
1998-12-16 |
2008-12-22 |
Novartis Vaccines & Diagnostic |
Quinase dependente de ciclina humana (hpnqalre)
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
NZ581940A
(en)
|
1999-04-30 |
2011-07-29 |
Novartis Vaccines & Diagnostic |
Conserved neisserial antigens
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
RU2281956C2
(ru)
|
1999-10-29 |
2006-08-20 |
Чирон С.Р.Л. |
Антигенные пептиды neisseria
|
EP2163626A1
(en)
|
1999-11-18 |
2010-03-17 |
Novartis Vaccines and Diagnostics, Inc. |
Human FGF-21 gene and gene expression products
|
DK2289545T3
(en)
|
2000-01-17 |
2016-09-05 |
Glaxosmithkline Biologicals Sa |
Supplemented OMV vaccine against meningococcus
|
US20020082205A1
(en)
|
2000-03-08 |
2002-06-27 |
Nobuyuki Itoh |
Human FGF-23 gene and gene expression products
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
WO2003057926A1
(en)
|
2002-01-08 |
2003-07-17 |
Chiron Corporation |
Gene products differentially expressed in cancerous breast cells and their methods of use
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
WO2001096523A2
(en)
|
2000-06-15 |
2001-12-20 |
Chiron Corporation |
Polynucleotides related to colon cancer
|
EP2189473A3
(en)
|
2000-10-27 |
2010-08-11 |
Novartis Vaccines and Diagnostics S.r.l. |
Nucleic and proteins from streptococcus groups A & B
|
JP2004535765A
(ja)
|
2000-12-07 |
2004-12-02 |
カイロン コーポレイション |
前立腺癌においてアップレギュレートされた内因性レトロウイルス
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
US7309783B2
(en)
|
2001-05-09 |
2007-12-18 |
The University Of Connecticut |
Mammalian early developmental regulator gene
|
KR20030022094A
(ko)
|
2001-05-24 |
2003-03-15 |
(주)휴먼디엔에이테크놀로지 |
모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
|
ES2345329T3
(es)
|
2001-11-09 |
2010-09-21 |
Georgetown University |
Nueva isoforma del inhibidor del crecimiento celular endotelial vascular (vegi).
|
JP4413617B2
(ja)
|
2001-12-12 |
2010-02-10 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
Chlamydiatrachomatisに対する免疫化
|
CA2479730A1
(en)
|
2002-03-21 |
2003-10-02 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
EP1532161B1
(en)
|
2002-06-13 |
2012-02-15 |
Novartis Vaccines and Diagnostics, Inc. |
Vectors for expression of hml-2 polypeptides
|
US7135324B2
(en)
|
2002-09-04 |
2006-11-14 |
The University Of Connecticut |
Viral recombinases, related articles, and methods of use thereof
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
DK2279746T3
(da)
|
2002-11-15 |
2013-11-25 |
Novartis Vaccines & Diagnostic |
Overfladeproteiner i neisseria meningitidis
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
KR101250818B1
(ko)
|
2002-12-24 |
2013-04-15 |
리나트 뉴로사이언스 코프. |
항-ngf 항체 및 그것을 이용하는 방법
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20070149449A1
(en)
|
2003-02-14 |
2007-06-28 |
Morris David W |
Therapeutic targets in cancer
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US7655231B2
(en)
|
2003-02-19 |
2010-02-02 |
Pfizer Inc. |
Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
ES2481167T3
(es)
|
2003-08-22 |
2014-07-29 |
Dupont Nutrition Biosciences Aps |
Composición que comprende una bacteriocina y un extracto de una planta de la familia Labiatae
|
GB2388581A
(en)
|
2003-08-22 |
2003-11-19 |
Danisco |
Coated aqueous beads
|
BRPI0417270A
(pt)
|
2003-12-23 |
2007-03-27 |
Rinat Neuroscience Corp |
anticorpos agonistas antitrkc e métodos para utilização dos mesmos
|
JP4792390B2
(ja)
|
2004-03-29 |
2011-10-12 |
株式会社ガルファーマ |
新規ガレクチン9改変体タンパク質及びその用途
|
NZ549990A
(en)
|
2004-04-07 |
2009-08-28 |
Rinat Neuroscience Copr |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
ES2673972T3
(es)
|
2004-07-09 |
2018-06-26 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Formas solubles de la glicoproteína G de los virus hendra y nipah
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
AP2007003890A0
(en)
|
2004-07-30 |
2007-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amy-loid-beta peptide and methods using same
|
EP1827385B1
(en)
|
2004-11-23 |
2013-03-27 |
Adamas Pharmaceuticals, Inc. |
Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
EP2623099A1
(en)
|
2004-11-24 |
2013-08-07 |
Neuromolecular Pharmaceuticals, Inc |
Composition and method for treating neurological disease
|
US7939490B2
(en)
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
MX291624B
(es)
|
2005-02-18 |
2011-11-04 |
Novartis Vaccines & Diagnostic |
Inmunogenos de escherichia coli uropatogenica.
|
PL1874282T3
(pl)
|
2005-04-06 |
2011-04-29 |
Adamas Pharmaceuticals Inc |
Sposoby i kompozycje do leczenia zaburzeń OUN
|
WO2006110585A2
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cancer-related genes (prlr)
|
AU2006235276A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
CACNA1E in cancer diagnosis, detection and treatment
|
PE20061323A1
(es)
|
2005-04-29 |
2007-02-09 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
|
US7462698B2
(en)
|
2005-07-22 |
2008-12-09 |
Y's Therapeutics Co., Ltd. |
Anti-CD26 antibodies and methods of use thereof
|
AP2008004467A0
(en)
|
2005-11-14 |
2008-06-30 |
Rinat Neurosciene Corp |
Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
|
JP2009525319A
(ja)
|
2006-02-02 |
2009-07-09 |
ライナット ニューロサイエンス コーポレイション |
trkBアンタゴニストを投与することにより肥満を治療する方法
|
CN103709252B
(zh)
|
2006-06-07 |
2016-12-07 |
生物联合公司 |
识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
|
PT2054431E
(pt)
|
2006-06-09 |
2011-11-03 |
Novartis Ag |
Confórmeros de adesinas bacterianas
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
EP2134365B1
(en)
|
2007-03-21 |
2019-03-13 |
Effat Emamian |
Compositions and methods for inhibiting tumor cell growth
|
WO2008124176A2
(en)
|
2007-04-10 |
2008-10-16 |
The Administrators Of The Tulane Educational Fund |
Soluble and membrane-anchored forms of lassa virus subunit proteins
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
KR20130087632A
(ko)
|
2007-12-17 |
2013-08-06 |
화이자 리미티드 |
간질성 방광염의 치료
|
RU2528738C2
(ru)
|
2007-12-18 |
2014-09-20 |
Биоэллаенс К.В. |
Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения
|
EP2274437B1
(en)
|
2008-04-10 |
2015-12-23 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9拮抗劑類
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
EP2403526B1
(en)
|
2009-03-06 |
2019-05-15 |
GlaxoSmithKline Biologicals SA |
Chlamydia antigens
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
JP5830009B2
(ja)
|
2009-04-14 |
2015-12-09 |
ノバルティス アーゲー |
Staphylococcusaureusに対して免疫化するための組成物
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
SG178035A1
(en)
|
2009-07-16 |
2012-03-29 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
EP3132793A1
(en)
|
2009-12-02 |
2017-02-22 |
Adamas Pharmaceuticals, Inc. |
Amantadine compositions and methods of use
|
AR080291A1
(es)
|
2010-02-24 |
2012-03-28 |
Rinat Neuroscience Corp |
Anticuerpos antagonistas anti receptor de il-7 y procedimientos
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2545079A2
(en)
|
2010-03-11 |
2013-01-16 |
Rinat Neuroscience Corporation |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
US9770414B2
(en)
*
|
2010-05-13 |
2017-09-26 |
Pacira Pharmaceuticals, Inc. |
Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
|
US8747844B2
(en)
|
2010-07-30 |
2014-06-10 |
Saint Louis University |
Methods of treating pain
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US20130071375A1
(en)
|
2011-08-22 |
2013-03-21 |
Saint Louis University |
Compositions and methods for treating inflammation
|
WO2013028527A1
(en)
|
2011-08-23 |
2013-02-28 |
Indiana University Research And Technology Corporation |
Compositions and methods for treating cancer
|
CN104053672A
(zh)
|
2011-11-11 |
2014-09-17 |
瑞纳神经科学公司 |
Trop-2特异性抗体及其用途
|
US9249224B2
(en)
|
2011-12-22 |
2016-02-02 |
Rinat Neuroscience Corp. |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
AU2013286866B2
(en)
|
2012-07-02 |
2018-03-01 |
Commonwealth Scientific And Industrial Research Organization |
Paramyxovirus and methods of use
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
KR20150082503A
(ko)
|
2012-11-09 |
2015-07-15 |
화이자 인코포레이티드 |
혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
|
US20160017055A1
(en)
|
2013-03-15 |
2016-01-21 |
Dyax Corp. |
Anti-plasma kallikrein antibodies
|
SG11201508264UA
(en)
|
2013-05-07 |
2015-11-27 |
Rinat Neuroscience Corp |
Anti-glucagon receptor antibodies and methods of use thereof
|
WO2014204933A1
(en)
|
2013-06-17 |
2014-12-24 |
Adamas Pharmaceuticals, Inc. |
Amantadine compositions and methods of use
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
MX371455B
(es)
|
2013-08-02 |
2020-01-28 |
Pfizer |
Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
|
PE20161092A1
(es)
|
2013-11-13 |
2016-10-28 |
Pfizer |
Anticuerpos especificos para el ligando 1a tipo factor de necrosis tumoral y composiciones y uso de ellos
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
JP6568099B2
(ja)
|
2014-03-21 |
2019-08-28 |
テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH |
カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
|
WO2015168474A1
(en)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
DK3283106T3
(da)
|
2015-04-13 |
2022-01-10 |
Pfizer |
Terapeutiske antistoffer og anvendelser deraf
|
CA2993026A1
(en)
|
2015-07-21 |
2017-01-26 |
Dyax Corp. |
A monoclonal antibody inhibitor of factor xiia
|
WO2017015334A1
(en)
|
2015-07-21 |
2017-01-26 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
CA3025896A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
CN107922506B
(zh)
|
2015-08-19 |
2021-11-09 |
辉瑞公司 |
组织因子途径抑制剂抗体及其用途
|
CN113896790A
(zh)
|
2015-09-15 |
2022-01-07 |
供石公司 |
抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
|
JP6661319B2
(ja)
*
|
2015-09-28 |
2020-03-11 |
小林製薬株式会社 |
リポソーム
|
CN109071648B
(zh)
|
2015-10-23 |
2022-07-19 |
辉瑞有限公司 |
抗il-2抗体及其组合物和用途
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
AU2016381964B2
(en)
|
2015-12-30 |
2024-02-15 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
EP3397253A1
(en)
|
2015-12-30 |
2018-11-07 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of seizure-related disorders
|
US10221242B2
(en)
|
2016-01-21 |
2019-03-05 |
Pfizer Inc. |
Antibodies specific for epidermal growth factor receptor variant III and their uses
|
KR102069670B1
(ko)
*
|
2017-03-02 |
2020-01-23 |
단디바이오사이언스 주식회사 |
면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
|
AU2018226646A1
(en)
|
2017-03-03 |
2019-09-19 |
Rinat Neuroscience Corp. |
Anti-GITR antibodies and methods of use thereof
|
CA3056182A1
(en)
|
2017-03-16 |
2018-09-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
WO2018191548A2
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
WO2018200885A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocentria, Inc. |
Magnesium compositions and methods of use
|
PE20191846A1
(es)
|
2017-06-02 |
2019-12-31 |
Pfizer |
Anticuerpos especificos para flt3 y sus usos
|
AU2018282865A1
(en)
|
2017-06-13 |
2019-12-19 |
Bostongene Corporation |
Systems and methods for generating, visualizing and classifying molecular functional profiles
|
US20190015473A1
(en)
|
2017-07-13 |
2019-01-17 |
Massachusetts Institute Of Technology |
Targeting the hdac2-sp3 complex to enhance synaptic funcation
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
US20200271657A1
(en)
|
2017-10-04 |
2020-08-27 |
Opko Pharmaceuticals, Llc |
Articles and methods directed to personalized therapy of cancer
|
CN111936519A
(zh)
|
2018-02-01 |
2020-11-13 |
辉瑞公司 |
对cd70具有特异性的抗体及其用途
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
AU2019228381B2
(en)
|
2018-02-28 |
2021-12-16 |
Pfizer Inc. |
IL-15 variants and uses thereof
|
PE20210127A1
(es)
|
2018-05-23 |
2021-01-19 |
Pfizer |
Anticuerpos especificos para cd3 y sus usos
|
TWI803637B
(zh)
|
2018-05-23 |
2023-06-01 |
美商輝瑞大藥廠 |
特異性針對gucy2c之抗體及其用途
|
CA3146077A1
(en)
|
2019-07-03 |
2021-02-18 |
Bostongene Corporation |
Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
|
EP4041308A1
(en)
|
2019-10-07 |
2022-08-17 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
JP2022553640A
(ja)
|
2019-10-10 |
2022-12-26 |
コディアック サイエンシーズ インコーポレイテッド |
眼障害を処置する方法
|
WO2021072244A1
(en)
|
2019-10-11 |
2021-04-15 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
WO2021224850A1
(en)
|
2020-05-06 |
2021-11-11 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
AU2021308586A1
(en)
|
2020-07-17 |
2023-03-02 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
CA3190227A1
(en)
|
2020-07-30 |
2022-02-03 |
Pfizer Inc. |
Cells having gene duplications and uses thereof
|
KR20230117327A
(ko)
|
2020-09-03 |
2023-08-08 |
어빈 에스.와이. 첸 |
가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
|
WO2022120256A2
(en)
|
2020-12-04 |
2022-06-09 |
Bostongene Corporation |
Hierarchical machine learning techniques for identifying molecular categories from expression data
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
WO2022232615A1
(en)
|
2021-04-29 |
2022-11-03 |
Bostongene Corporation |
Machine learning techniques for estimating tumor cell expression complex tumor tissue
|
EP4380969A1
(en)
|
2021-08-02 |
2024-06-12 |
Pfizer Inc. |
Improved expression vectors and uses thereof
|
WO2023147177A1
(en)
|
2022-01-31 |
2023-08-03 |
Bostongene Corporation |
Machine learning techniques for cytometry
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
US20240029884A1
(en)
|
2022-07-15 |
2024-01-25 |
Bostongene Corporation |
Techniques for detecting homologous recombination deficiency (hrd)
|